{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:42Z","timestamp":1761986562798,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,4,26]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>A Caucasian man in his 60s with a medical history significant for ruptured left middle cerebral artery aneurysm status post clipping 2005 with residual right eye blindness and right leg weakness with gait instability presented with loss of balance, weakness of his legs and fatigue for 3\u2009days. No other antecedent event was identified other than receiving Moderna COVID-19 vaccine 4 weeks before the presentation and 3\u2009days before symptom onset. CT head and CT angiogram of the head and neck were performed and demonstrated no acute intracranial bleeding and no vascular abnormalities. With the findings of diffuse hyporeflexia and cerebrospinal fluid showing albumino-cytological dissociation, Guillain-Barr\u00e9 syndrome was high on the differentials. Electromyogram showed evidence of demyelination. He was treated with intravenous immune globulin (IVIG) and was discharged to rehab with complete symptom resolution.<\/jats:p>","DOI":"10.1136\/bcr-2022-249749","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T12:46:34Z","timestamp":1653309994000},"page":"e249749","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Rare occurrence of Guillain-Barr\u00e9 syndrome after Moderna vaccine"],"prefix":"10.1136","volume":"15","author":[{"given":"Tissa","family":"Bijoy George","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Pittsburgh Medical Center Health System, McKeesport, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleesha","family":"Kainat","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Pittsburgh Medical Center Health System, McKeesport, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranali Santhoshini","family":"Pachika","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Pittsburgh Medical Center Health System, McKeesport, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Arnold","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Pittsburgh Medical Center Health System, McKeesport, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"2025082623292467000_15.5.e249749.1","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082623292467000_15.5.e249749.2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"The Lancet"},{"key":"2025082623292467000_15.5.e249749.3","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795"},{"key":"2025082623292467000_15.5.e249749.4","unstructured":"Coronavirus Disease (COVID-19) - events as they happen [Internet]. Who.int, 2022. Available: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/events-as-they-happen"},{"key":"2025082623292467000_15.5.e249749.5","doi-asserted-by":"crossref","unstructured":"Halim M . COVID-19 vaccination efficacy and safety literature review. J Immuno Allerg 2021.doi:10.37191\/Mapsci-2582-4333-3(1)-058","DOI":"10.37191\/Mapsci-2582-4333-3(1)-058"},{"key":"2025082623292467000_15.5.e249749.6","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025082623292467000_15.5.e249749.7","doi-asserted-by":"crossref","unstructured":"Koreen R , DO JC , Hackensack Meridian Palisades Medical Center, North Bergen . The development of Guillain Barre syndrome subsequent to administration of Ad26.COV2.S vaccine. J Neurol Res Rev Rep 2021:1\u20133.doi:10.47363\/JNRRR\/2021(3)140","DOI":"10.47363\/JNRRR\/2021(3)140"},{"key":"2025082623292467000_15.5.e249749.8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244125","article-title":"Guillain-Barr\u00e9 syndrome after COVID-19 vaccination","volume":"14","author":"McKean","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025082623292467000_15.5.e249749.9","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Grimshaw M , Michel-Ch\u00e1vez A , Vera-Zertuche JM . Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021.doi:10.1016\/j.clim.2021.108818","DOI":"10.1016\/j.clim.2021.108818"},{"key":"2025082623292467000_15.5.e249749.10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of recurrent Guillain-Barr\u00e9 syndrome after mRNA COVID-19 vaccine BNT162b2","volume":"78","author":"Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025082623292467000_15.5.e249749.11","article-title":"Axonal-variant guillian-Barre syndrome temporally associated with mRNA-based Moderna SARS-CoV-2 vaccine","volume":"13","author":"Dalwadi","year":"2021","journal-title":"Cureus"},{"key":"2025082623292467000_15.5.e249749.12","doi-asserted-by":"crossref","first-page":"108818","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"2025082623292467000_15.5.e249749.13","unstructured":"Christensen SK , Ballegaard M , Boesen MS . Guillian Barr\u00e9 syndromeafter mRNA-1273 vaccination against COVID-19. Ugeskr Laeger 2021;183."},{"key":"2025082623292467000_15.5.e249749.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00195-2"},{"key":"2025082623292467000_15.5.e249749.15","doi-asserted-by":"publisher","DOI":"10.1159\/000324710"},{"key":"2025082623292467000_15.5.e249749.16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440512"},{"key":"2025082623292467000_15.5.e249749.17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314862"},{"key":"2025082623292467000_15.5.e249749.18","article-title":"Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"key":"2025082623292467000_15.5.e249749.19","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA"},{"key":"2025082623292467000_15.5.e249749.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70140-7"},{"key":"2025082623292467000_15.5.e249749.21","unstructured":"Guillain-Barr\u00e9 syndrome (GBS) after Janssen COVID-19 vaccine: Vaccine adverse event reporting system (VAERS) meeting of the advisory committee on immunization practices (ACIP) [Internet]. Cdc.gov, 2021. Available: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-07\/02-covid-alimchandani-508.pdf"},{"key":"2025082623292467000_15.5.e249749.22","unstructured":"Europa.eu, 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf"},{"key":"2025082623292467000_15.5.e249749.23","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138234"},{"key":"2025082623292467000_15.5.e249749.24","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1080\/21645515.2021.1954826","article-title":"Electromyoneurography and laboratory findings in a case of Guillain-Barr\u00e9 syndrome after second dose of Pfizer COVID-19 vaccine","volume":"17","author":"Scendoni","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2025082623292467000_15.5.e249749.25","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1007\/s10072-021-05523-5","article-title":"Guillain-Barr\u00e9 syndrome following BNT162b2 COVID-19 vaccine","volume":"42","author":"Trimboli","year":"2021","journal-title":"Neurol Sci"},{"key":"2025082623292467000_15.5.e249749.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15072"},{"key":"2025082623292467000_15.5.e249749.27","unstructured":"Office of the Commissioner . Coronavirus (COVID-19) update: July 13, 2021 [Internet]. U.S. Food and Drug Administration. 2021, 2021. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-july-13-2021"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-249749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:29:38Z","timestamp":1756276178000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-249749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,9]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bcr-2022-249749"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-249749","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}